An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth

Author(s): Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki, Frank Bruchertseifer.

Journal Name: Current Radiopharmaceuticals

Volume 11 , Issue 3 , 2018

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.

Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.

Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, nuclide production, clinical application.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 11
ISSUE: 3
Year: 2018
Page: [200 - 208]
Pages: 9
DOI: 10.2174/1874471011666180502104524

Article Metrics

PDF: 114
HTML: 17
EPUB: 1
PRC: 1